不同剂量非布司他对痛风伴高尿酸血症患者血尿酸水平及血清ET-1、NO和MPO的影响

摘要

Objective To investigate effects of different doses of Buprenorphine on levels of serum uric acid and serum endothelin-1 (ET-1),nitric oxide (NO) and myeloperoxidase (MPO) of patients with gout associated by hyperuricemia.Methods Clinical data of 60 patients with gout associated by hyperuricemia during October 2013 and December 2014 was retrospectively analyzed,and the patients were divided into group A,B and C (n =20 for each group) according to admission time.Group A was treated with 40 mg Bupivacaine tablets;group B was treated with 80 mg Bupivacaine tablets;group C was given 300 mg of Allopurinol tablets.The course of treatment was 24 weeks.Level changes of serum uric acid,ET-1,NO,MPO and incidence of adverse reactions were detected and recorded 1 day before treatment,12 weeks and 24 weeks after treatment in three groups.Results Compared with those 1 day before treatment,serum uric acid,ET-1 and MPO levels were significantly lower,while NO levels were significantly higher 12 weeks and 24 weeks after treatment in three groups (P ＜0.05).In group B,ET-1 level 24 weeks after treatment was significantly lower than that 12 weeks after treatment (P ＜0.05).No severe adverse reaction was found in three groups.Conclusion Different doses of Buprenorphine and Allopurinol tablets can effectively decrease serum blood uric acid and ET-1 levels of patients with gout associated by hyperuricemia,and 40mg Buprenorphine tablets has good stability and high safety in improvement of inflammation.%目的 探讨不同剂量非布司他对痛风伴高尿酸血症患者血尿酸水平及血清内皮素-1(ET-1)、一氧化氮(NO)和髓过氧化物酶(MPO)的影响.方法 对2013年10月-2014年12月诊治的痛风伴高尿酸血症60例的临床资料进行回顾性分析.根据入院时间分为A、B、C组,每组20例.A组应用非布司他片40 mg,B组给予非布司片他80 mg,C组给予别嘌呤醇片300 mg.治疗疗程均为24周.检测并记录3组治疗前1d、治疗12和24周后血尿酸水平、血清ET-1、NO、MPO水平变化及不良反应发生情况.结果 与治疗前1d相比,3组治疗后12、24周后血尿酸、ET-1、MPO水平降低,NO水平升高,B组治疗24周后血清ET-1水平低于治疗12周后(P＜0.05).3组均未出现严重不良反应.结论 不同剂量非布司他片及别嘌呤醇片均能有效降低痛风伴高尿酸血症患者血清ET-1与血尿酸水平,40 mg非布司他片改善患者炎症状态稳定性好,且安全性较高.